Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Piotr Radojewski
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Piotr Radojewski wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. 2019

Kaderli, Reto M / Spanjol, Marko / Kollár, Attila / Bütikofer, Lukas / Gloy, Viktoria / Dumont, Rebecca A / Seiler, Christian A / Christ, Emanuel R / Radojewski, Piotr / Briel, Matthias / Walter, Martin A. ·Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland. · Department of Nuclear Medicine, University Hospital, University of Geneva, Geneva, Switzerland. · Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland. · Clinical Trials Unit Bern, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. · Department of Endocrinology, Diabetes, and Metabolism, Basel University Hospital, University of Basel, Basel, Switzerland. · Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, Basel University Hospital, University of Basel, Basel, Switzerland. · Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. ·JAMA Oncol · Pubmed #30763436.

ABSTRACT: Importance: Multiple therapies are currently available for patients with neuroendocrine tumors (NETs), yet many therapies have not been compared head-to-head within randomized clinical trials (RCTs). Objective: To assess the relative safety and efficacy of therapies for NETs. Data Sources: PubMed, Embase, the Cochrane Central Register of Controlled Trials, trial registries, meeting abstracts, and reference lists from January 1, 1947, to March 2, 2018, were searched. Key search terms included neuroendocrine tumors, gastrointestinal neoplasms, therapy, and randomized controlled trial. Study Selection: Randomized clinical trials comparing 2 or more therapies in patients with NETs (primarily gastrointestinal and pancreatic) were evaluated. Thirty RCTs met the selection criteria. Data Extraction and Synthesis: Pairs of independent reviewers screened studies, extracted data, and assessed the risk of bias. A network meta-analysis with a frequentist approach was used to compare the efficacy of therapies; the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline was used. Main Outcomes and Measures: Disease control, progression-free survival, overall survival, adverse events, and quality of life. Results: The systematic review identified 30 relevant RCTs comprising 3895 patients (48.4% women) assigned to 22 different therapies for NETs. These therapies showed a broad range of risk for serious and nonserious adverse events. The network meta-analyses included 16 RCTs with predominantly a low risk of bias; nevertheless, precision-of-treatment estimates and estimated heterogeneity were limited. The network meta-analysis found 7 therapies for pancreatic NETs: everolimus (hazard ratio [HR], 0.35 [95% CI, 0.28-0.45]), everolimus plus somatostatin analogue (HR, 0.35 [95% CI, 0.25-0.51]), everolimus plus bevacizumab plus somatostatin analogue (HR, 0.44 [95% CI, 0.26-0.75]), interferon (HR, 0.37 [95% CI, 0.16-0.83]), interferon plus somatostatin analogue (HR, 0.31 [95% CI, 0.13-0.71]), somatostatin analogue (HR, 0.46 [95% CI, 0.33-0.66]), and sunitinib (HR, 0.42 [95% CI, 0.26-0.67]), and 5 therapies for gastrointestinal NETs: bevacizumab plus somatostatin analogue (HR, 0.22 [95% CI, 0.05-0.99]), everolimus plus somatostatin analogue (HR, 0.31 [95% CI, 0.11-0.90]), interferon plus somatostatin analogue (HR, 0.27 [95% CI, 0.07-0.96]), Lu 177-dotatate plus somatostatin analogue (HR, 0.08 [95% CI, 0.03-0.26], and somatostatin analogues (HR, 0.40 [95% CI, 0.21-0.78]) with higher efficacy than placebo and suggests an overall superiority of combination therapies. Conclusions and Relevance: The findings from this study suggest that a range of efficient therapies with different safety profiles is available for patients with NETs.

2 Article The prognostic and predictive value of sstr 2017

Brunner, Philippe / Jörg, Ann-Catherine / Glatz, Katharina / Bubendorf, Lukas / Radojewski, Piotr / Umlauft, Maria / Marincek, Nicolas / Spanjol, Petar-Marko / Krause, Thomas / Dumont, Rebecca A / Maecke, Helmut R / Müller-Brand, Jan / Briel, Matthias / Schmitt, Anja / Perren, Aurel / Walter, Martin A. ·Institute of Pathology, University Hospital Basel, CH, Basel, Switzerland. · Institute of Nuclear Medicine, University Hospital Basel, CH, Basel, Switzerland. · Institute of Nuclear Medicine, University Hospital Bern, CH, 3010, Bern, Switzerland. · Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland. · Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, CH, Switzerland. · Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada. · Institute of Pathology, University Bern, Bern, Switzerland. · Institute of Nuclear Medicine, University Hospital Bern, CH, 3010, Bern, Switzerland. m.a.walter@gmx.net. ·Eur J Nucl Med Mol Imaging · Pubmed #27539020.

ABSTRACT: PURPOSE: Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr METHODS: We established a tissue microarray and imaging database from NET patients that received sstr RESULTS: We included a total of 279 patients. In these patients, sstr CONCLUSIONS: Our results suggest sstr